Gilead Sciences (NASDAQ:GILD)

Analysts See 10 Companies Beating Expectations This Earnings Season

With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for ...
Read Full Story »

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, March 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

If any industry has been under pressure over the past year or so, it has been biotechnology. While there are some positives for the industry, it still faces some definite ...
Read Full Story »

Short Interest Pulls Back in Major Biotechs

The short interest data are out for the most recent settlement date, March 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

How Health Care Stocks Responded to the Shelved Health Care Bill

Despite touting himself as an incredible dealmaker and negotiater, Trump faced the biggest defeat of his presidency thus far when legislation to repeal the Affordable Care Act was pulled from ...
Read Full Story »

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

If any sector is offering value in what really appears to be a very overbought stock market, it is pharmaceutical, including biotechnology. Absolutely battered during the election cycle when rhetoric over ...
Read Full Story »

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences Inc. (NASDAQ: GILD) has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AIG, Boeing, GameStop, Gilead, Starbucks, CIGNA, Ciena, Ferrari and Many More

Stocks were indicated to open marginally higher on Monday, but all eyes remain on the Federal Open Market Committee (FOMC) ahead of this week's interest rate hike decision. The odds ...
Read Full Story »

Major Biotechs See a Retreat in Short Interest

The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Stocks were indicated lower on Thursday ahead of Friday's key payrolls and unemployment report. The European Central Bank maintained rates at 0.00%. Now that the bull market is officially eight years ...
Read Full Story »
biotech word cloud

Short Sellers Hike Their Bets in Major Biotechs

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Chevron logo

Jefferies Says Buy These Dividend-Paying Companies That Missed Expectations

We have written on numerous occasions that it has become harder with each passing trading day to find stocks that are not sky-high expensive. We are in the phase of ...
Read Full Story »
Medical vaccine in shoulder, vaccination

What Analysts Are Prescribing Gilead After Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The stock hit a new multiyear low on Wednesday and pushed even lower on Thursday to a price ...
Read Full Story »
Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Stock Price

Vista Outdoor, Fossil Group Dive into Thursday’s 52-Week Low Club

February 9, 2017: Here are four stocks trading with relatively heavy volume among 35 equities making new 52-week lows in Thursday's session. On the NYSE, advancers led decliners nearly 2 ...
Read Full Story »